![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Molecular Pharmacology, Volume 52, Issue 5, 829-838
Departments of Biochemistry and Molecular Biology (G.M.G., D.A.F., J.-P.F., M.O., M.D.P, J.A.M., G.P.O) and Medicinal Chemistry (P.R., C.B.), Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Québec H9R 4P8, Canada
The three-dimensional cocrystal structures of ovine prostaglandin G/H synthase-1 (PGHS-1) with S-flurbiprofen and murine PGHS-2 with S-flurbiprofen and indomethacin reveal that the carboxylate acid groups of these nonsteroidal anti-inflammatory drugs (NSAIDs) form a salt bridge with the guanidinium group of Arg120 in PGHS-1 and Arg106 in PGHS-2. Mutagenesis studies confirmed that the Arg120 residue of PGHS-1 is critical for binding of substrate and inhibitors through ionic interactions of its guanidinium group with the carboxylate moieties of arachidonic acid and certain NSAIDs. We report here that the analogous R106E substitution in human PGHS-2 results in a catalytically active enzyme with a 30-fold higher Km value for arachidonic acid. Comparison of the inhibition of hPGHS-2(R106E) with wild-type hPGHS-2 by 11 structurally diverse selective and nonselective PGHS inhibitors revealed a 0-1000-fold decrease in inhibitory potency on the mutant enzyme. The loss of inhibitory potency of NSAIDs on hPGHS-2(R106E) could not be correlated with the presence or absence of a carboxylate functional group in the inhibitor, as was demonstrated previously for the PGHS-1(R120E) mutant, or with the selective or nonselective nature of the PGHS inhibitor. The decreases in the inhibitory potencies on hPGHS-2(R106E) by the carboxylate-containing NSAIDs flurbiprofen, indomethacin, meclofenamic acid, and diclofenac on hPGHS-2(R106E) were 965-, 48-, 5.5-, and 4.5-fold, respectively. The nonuniversal requirement for interaction of the carboxylate group of certain NSAIDs with the Arg106 residue in hPGHS-2 is supported by the observation that the methyl ester derivative of indomethacin was a more potent inhibitor than indomethacin on both hPGHS-2 and hPGHS-2(R106E). The greatest loss of potency for inhibition of hPGHS-2(R106E) was observed with the hPGHS-2-selective sulfonamide-containing inhibitors NS-398 and flosulide. The PGHS-2-selective inhibitor DuP697 and a desbromo-sulfonamide analogue of DuP697 displayed equivalent potency on hPGHS-2(R106E) and hPGHS-2. The change in inhibitory potency of NS-398 on hPGHS-2(R106E) was due to a difference in the kinetics of inhibition, with NS-398 displaying time-dependent inhibition of hPGHS-2 but time-independent inhibition of PGHS-2(R106E). The time-dependent inhibition of hPGHS-2 by DuP697 was not affected by the presence of the R106E mutation. We conclude that the Arg106 residue of hPGHS-2 is involved in binding arachidonic acid and certain NSAIDs, but interactions with Arg106 are not a universal requirement for inhibition by either carboxylate-containing NSAIDs or PGHS-2-selective inhibitors.
This article has been cited by other articles:
|
|
 |
|
  C. A. Harman, M. V. Turman, K. R. Kozak, L. J. Marnett, W. L. Smith, and R. M. Garavito Structural Basis of Enantioselective Inhibition of Cyclooxygenase-1 by S-{alpha}-Substituted Indomethacin Ethanolamides J. Biol. Chem., September 21, 2007; 282(38): 28096 - 28105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Rouzer and L. J. Marnett Glycerylprostaglandin Synthesis by Resident Peritoneal Macrophages in Response to a Zymosan Stimulus J. Biol. Chem., July 22, 2005; 280(29): 26690 - 26700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Rouzer, A. T. Jacobs, C. S. Nirodi, P. J. Kingsley, J. D. Morrow, and L. J. Marnett RAW264.7 cells lack prostaglandin-dependent autoregulation of tumor necrosis factor-{alpha} secretion J. Lipid Res., May 1, 2005; 46(5): 1027 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Rouzer, P. J. Kingsley, H. Wang, H. Zhang, J. D. Morrow, S. K. Dey, and L. J. Marnett Cyclooxygenase-1-dependent Prostaglandin Synthesis Modulates Tumor Necrosis Factor-{alpha} Secretion in Lipopolysaccharide-challenged Murine Resident Peritoneal Macrophages J. Biol. Chem., August 13, 2004; 279(33): 34256 - 34268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Rowlinson, J. R. Kiefer, J. J. Prusakiewicz, J. L. Pawlitz, K. R. Kozak, A. S. Kalgutkar, W. C. Stallings, R. G. Kurumbail, and L. J. Marnett A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385 J. Biol. Chem., November 14, 2003; 278(46): 45763 - 45769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Hood, J. K. Gierse, P. C. Isakson, J. R. Kiefer, R. G. Kurumbail, K. Seibert, and J. B. Monahan Characterization of Celecoxib and Valdecoxib Binding to Cyclooxygenase Mol. Pharmacol., April 1, 2003; 63(4): 870 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Catella-Lawson, M. P. Reilly, S. C. Kapoor, A. J. Cucchiara, S. DeMarco, B. Tournier, S. N. Vyas, and G. A. FitzGerald Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin N. Engl. J. Med., December 20, 2001; 345(25): 1809 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Hewett, T. F. Uliasz, A. S. Vidwans, and J. A. Hewett Cyclooxygenase-2 Contributes to N-Methyl-D-aspartate-Mediated Neuronal Cell Death in Primary Cortical Cell Culture J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 417 - 425. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. S. Kalgutkar, B. C. Crews, S. W. Rowlinson, A. B. Marnett, K. R. Kozak, R. P. Remmel, and L. J. Marnett Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors PNAS, January 18, 2000; 97(2): 925 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Rieke, A. M. Mulichak, R. M. Garavito, and W. L. Smith The Role of Arginine 120 of Human Prostaglandin Endoperoxide H Synthase-2 in the Interaction with Fatty Acid Substrates and Inhibitors J. Biol. Chem., June 11, 1999; 274(24): 17109 - 17114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. DeWitt Cox-2-Selective Inhibitors: The New Super Aspirins Mol. Pharmacol., April 1, 1999; 55(4): 625 - 631. [Full Text]
|
|
|
|
|
|
K. C. Zimmermann, M. Sarbia, K. Schrör, and A.-A. Weber Constitutive Cyclooxygenase-2 Expression in Healthy Human and Rabbit Gastric Mucosa Mol. Pharmacol., September 1, 1998; 54(3): 536 - 540. [Abstract] [Full Text]
|
|
|
|
|
|
K. R. Kozak, S. W. Rowlinson, and L. J. Marnett Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2 J. Biol. Chem., October 20, 2000; 275(43): 33744 - 33749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Thuresson, K. M. Lakkides, C. J. Rieke, Y. Sun, B. A. Wingerd, R. Micielli, A. M. Mulichak, M. G. Malkowski, R. M. Garavito, and W. L. Smith Prostaglandin Endoperoxide H Synthase-1. THE FUNCTIONS OF CYCLOOXYGENASE ACTIVE SITE RESIDUES IN THE BINDING, POSITIONING, AND OXYGENATION OF ARACHIDONIC ACID J. Biol. Chem., March 23, 2001; 276(13): 10347 - 10357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Kozak, J. J. Prusakiewicz, S. W. Rowlinson, C. Schneider, and L. J. Marnett Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the Endocannabinoid 2-Arachidonylglycerol J. Biol. Chem., August 3, 2001; 276(32): 30072 - 30077. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
